Our study revealed that high expression of TAS2R10, TAS2R3, and TAS2R50 is significantly associated with poor prognosis in ovarian cancer, as demonstrated by our analysis of clinical samples (Figure 5D). This evidence concerns the gene TAS2R50 and ovarian cancer.